Medifast Analyst Ratings
Medifast Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/22/2023 | -11.01% | DA Davidson | $106 → $94 | Maintains | Neutral |
| 11/04/2022 | 0.35% | DA Davidson | $278 → $106 | Downgrades | Buy → Neutral |
| 08/04/2022 | 163.18% | DA Davidson | $352 → $278 | Maintains | Buy |
| 08/04/2022 | 42.01% | Jefferies | $345 → $150 | Downgrades | Buy → Hold |
| 06/02/2022 | 233.24% | DA Davidson | $341 → $352 | Maintains | Buy |
| 02/24/2022 | 222.82% | DA Davidson | $349 → $341 | Maintains | Buy |
| 11/08/2021 | 230.4% | DA Davidson | $395 → $349 | Maintains | Buy |
| 05/05/2021 | 273.95% | DA Davidson | $302 → $395 | Maintains | Buy |
| 02/26/2021 | 185.9% | DA Davidson | $239 → $302 | Maintains | Buy |
| 01/25/2021 | 150.88% | Jefferies | $205 → $265 | Upgrades | Hold → Buy |
| 01/12/2021 | 126.26% | DA Davidson | $205 → $239 | Maintains | Buy |
| 11/05/2020 | 94.07% | DA Davidson | $180 → $205 | Upgrades | Neutral → Buy |
| 06/25/2020 | 55.26% | B. Riley Securities | → $164 | Initiates Coverage On | → Buy |
| 05/06/2020 | -18.58% | DA Davidson | $83 → $86 | Maintains | Neutral |
| 02/27/2020 | -21.42% | DA Davidson | $74 → $83 | Maintains | Neutral |
| 11/08/2019 | -29.94% | DA Davidson | $250 → $74 | Downgrades | Buy → Neutral |
| 07/25/2019 | 23.07% | Jefferies | → $130 | Initiates Coverage On | → Buy |
| 02/27/2019 | 104.49% | Sidoti & Co. | $211 → $216 | Maintains | Buy |
| 11/08/2018 | — | Sidoti & Co. | Upgrades | Neutral → Buy | |
| 05/24/2018 | 52.42% | DA Davidson | $135 → $161 | Maintains | Buy |
| 04/19/2018 | — | Sidoti & Co. | Downgrades | Buy → Neutral |
| 日期 | 上/下行 | 分析師公司 | 价格目標變更 | 評級變更 | 上一頁/目前評分 |
|---|---|---|---|---|---|
| 02/22/2023 | -11.01% | 达戴维森 | 一百零二元 → 九十四美元 | 維護 | 中性 |
| 11/04/2022 | 0.35% | 达戴维森 | 二七八美元 → 106 美元 | 降級 | 購買 → 中性 |
| 2022 年 4 月 8 日 | 163.18% | 达戴维森 | 三五二元 → 二七八美元 | 維護 | 購買 |
| 2022 年 4 月 8 日 | 42.01% | 富瑞集團 | 三五元 → 150 美元 | 降級 | 購買 → 持有 |
| 2022 年 6 月 2 日 | 233.24% | 达戴维森 | 三四一元 → 三五二 | 維護 | 購買 |
| 2022 年 2 月 24 日 | 222.82% | 达戴维森 | 三四九元 → 三四十一美元 | 維護 | 購買 |
| 11/08/2021 | 230.4% | 达戴维森 | 三百九十五元 → 三四十九美元 | 維護 | 購買 |
| 2021 年 5 月 5 日 | 273.95% | 达戴维森 | 三零二元 → 三九五美元 | 維護 | 購買 |
| 02/26/2021 | 185.9% | 达戴维森 | 二三九元 → 三百零二美元 | 維護 | 購買 |
| 01/25/2021 | 150.88% | 富瑞集團 | 二百五十五美元 → | 升級 | 持有 → 購買 |
| 01/12/2021 | 126.26% | 达戴维森 | 二零五美元 → 二三九美元 | 維護 | 購買 |
| 11/05/2020 | 94.07% | 达戴维森 | 一百八十元 → 205 美元 | 升級 | 中性 → 購買 |
| 06/25/2020 | 55.26% | B. 萊利證券 | → | 啟動覆蓋範圍 | → 購買 |
| 2020 年 5 月 6 日 | -18.58% | 达戴维森 | 八三元 → 八十六美元 | 維護 | 中性 |
| 02/27/2020 | -21.42% | 达戴维森 | 74 美元 → 83 美元 | 維護 | 中性 |
| 11/08/2019 | -29.94% | 达戴维森 | 二百五十元 → 74 美元 | 降級 | 購買 → 中性 |
| 07/25/2019 | 23.07% | 富瑞集團 | → 一百三十美元 | 啟動覆蓋範圍 | → 購買 |
| 02/27/2019 | 104.49% | 西多迪 & 有限公司. | 二一零一元 → 二十六美元 | 維護 | 購買 |
| 11/08/2018 | — | 西多迪 & 有限公司. | 升級 | 中性 → 購買 | |
| 2018 年 5 月 24 日 | 52.42% | 达戴维森 | 一百五十五美元 → 161 美元 | 維護 | 購買 |
| 04/19/2018 | — | 西多迪 & 有限公司. | 降級 | 購買 → 中性 |
What is the target price for Medifast (MED)?
快驗保 (MED) 的目標價格是多少？
The latest price target for Medifast (NYSE: MED) was reported by DA Davidson on February 22, 2023. The analyst firm set a price target for $94.00 expecting MED to fall to within 12 months (a possible -11.01% downside). 6 analyst firms have reported ratings in the last year.
DA 戴維森於 2023 年 2 月 22 日報導了最新的價格目標（紐約證交所代碼：MED）。該分析師公司設定了 94.00 美元的價格目標，預計 MED 將在 12 個月內下降（可能為 -11.01％ 的下行）。6 分析師公司在去年報告了評級。
What is the most recent analyst rating for Medifast (MED)?
快驗保（MED）的最新分析師評級是什麼？
The latest analyst rating for Medifast (NYSE: MED) was provided by DA Davidson, and Medifast maintained their neutral rating.
最新的分析師評級為快驗保 (紐約證券交易所:MED) 是由 DA Davidson 提供, 和快驗保保持其中立的評級.
When is the next analyst rating going to be posted or updated for Medifast (MED)?
何時為快驗保（MED）發布或更新下一個分析師評級？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medifast, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medifast was filed on February 22, 2023 so you should expect the next rating to be made available sometime around February 22, 2024.
分析師在做廣泛的研究後到達股票評級, 其中包括通過公共財務報表去, 與快驗保的高管和客戶交談, 和收益電話會議.大多數分析師每三個月這樣做一次，因此您應該每年每家公司獲得 4 個評級。最後一個評級為快驗保提交 2 月 22, 2023 所以你應該期望下一個評級將在二月左右提供 22, 2024.
Is the Analyst Rating Medifast (MED) correct?
分析師評級快驗保（MED）是否正確？
While ratings are subjective and will change, the latest Medifast (MED) rating was a maintained with a price target of $106.00 to $94.00. The current price Medifast (MED) is trading at is $105.63, which is out of the analyst's predicted range.
儘管評級是主觀的並且會發生變化，但最新的快驗保（MED）評級保持了 106.00 美元至 94.00 美元的目標價格。目前的價格快驗保 (MED) 交易在 $105.63, 這是超出分析師的預測範圍.
譯文內容由第三人軟體翻譯。